Precision medicine becomes reality—tumor type-agnostic therapy

Explore this paper's citation graph

Summary

Larotrectinib (LOXO-101), Loxooncology’s oral, potent, and selective inhibitor of tropomyosin receptor kinases (TRK), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosa receptor kinase (NTRK)-fusion proteins in adult and pediatric patients, establishing a precedent for tumor type-agnostic therapy.

Type
review
Published
2018-03-31
Cited by
107
References
19
Access
Open access

Keywords

Precision medicine, Psychology, Medicine, Medical physics, Computer science

References

Cited by

Related papers